By Claudia Assis
‘Active discussions’ being held, telehealth company Hims & Hers says
Wegovy pens at a Chicago pharmacy. Telehealth company Hims & Hers says that it could be selling the GLP-1 medication on its platform soon.
Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform.
The discussions are about both Wegovy injections and an oral Wegovy, which is under evaluation in the U.S. and would be the first pill formulation of a GLP-1 medication if approved. The Food and Drug Administration is expected to rule on the oral Wegovy by the end of the year.
Hims & Hers said that the discussions with Novo Nordisk (DK:NOVO.B) are ongoing, that “no definitive agreement” has been reached, and that the two companies may not reach one. Nonetheless, Hims & Hers shares (HIMS) shot up 5.7% in the after-hours session Monday, after ending the regular trading day down more than 2%.
The disclosure of talks around the GLP-1 drug came as Hims, known for its streaming-TV commercials about erectile dysfunction, hair loss and other ailments, reported its third-quarter earnings.
The company reported third-quarter per-share earnings of 6 cents on revenue of $599 million, up 49% year over year. The EPS came in line with FactSet consensus, while revenue topped views.
Hims also reported a 21% growth in the number of subscribers in the quarter, to 2.5 million people.
The company said it expects revenue between $605 million and $625 million in the fourth quarter, and of $2.335 billion to $2.355 billion for the full year. Both outlooks are above expectations.
-Claudia Assis
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-03-25 2358ET
Copyright (c) 2025 Dow Jones & Company, Inc.